The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial (EPIC)

Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for1st Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

This is a randomized phase III trial that will randomize elderly patients(70 years of age and older) who are not considered eligible for standard doublet or triplet regimens. In a 2:1 fashion, patients will be randomized to the customization arm or the standard arm, respectively. This trial will be offered to patients who are previously untreated for stage IV NSCLC.

The primary objective is to evaluate if chemotherapy selection based on histology and tumoral molecular determinants ERCC1, RRM1 and TS (arm A, the experimental arm) results in superior outcome in elderly patients with untreated, advanced NSCLC compared to standard of care treatments (arm B, the standard arm).

Study Overview

• Status: Unknown
• Conditions: Neoplasms; Respiratory Tract Diseases; Lung Diseases; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Stage IV, NSCLC
• Intervention / Treatment: Drug: Gemcitabine; Drug: Docetaxel; Drug: Pemetrexed; Drug: Carboplatin; Drug: Vinorelbine

Detailed Description

The study population will consist of patients with histologically or cytologically proven stage IV NSCLC, who have not been previously treated with chemotherapy for stage IV and are either elderly (70 years of age and older). Patients must fulfill all the inclusion/exclusion criteria to be eligible.

Tissue will be obtained, and gene expression analysis will be performed at the University of Turin. The tissue sample used for this analysis will be obtained from the biopsy procedure performed as standard of care procedures during the patient's diagnosis and staging. Patients will be randomized to either Arm A: Experimental or Arm B: Standard of Care in a 2:1 fashion.

Tissue will be obtained for gene analysis for ALL patients. However, ONLY patients randomized to Arm A will receive the genetic analysis results. Genetic results will not be disclosed to the registering center for those patients randomized to Arm B: Standard of Care.

For patients randomized to Arm A: Experimental arm, the chemotherapy treatment prescription will be based on the gene analysis according to the protocol. For patients randomized to Arm B: Standard of Care arm, the chemotherapy treatment will be at the discretion of the care provider.

• Study Type: Interventional
• Enrollment (Anticipated): 567
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Silvia Novello, MD,PhD; Phone Number: +390119026978; Email: silvia.novello@unito.it

Study Locations

• Italy
  • Bari, Italy
    • Recruiting
    • Ospedale Giovanni Paolo II
  • Catania, Italy
    • Recruiting
    • AO Cannizzaro
    • Contact: Giuseppe Banna, MD
  • Cuneo, Italy
    • Recruiting
    • AOU Santa Croce e Carle
    • Contact: Ida Colantonio, MD
  • Firenze, Italy
    • Recruiting
    • Azienda Ospedaliera Careggi
    • Contact: Fabiana Cecere, MD
  • Genova, Italy
    • Recruiting
    • Ospedale Galliera
    • Contact: Carlotta Defferrari, MD
  • Genova, Italy
    • Recruiting
    • Istituto nazionale Per la Ricerca sul Cancro
  • Milano, Italy
    • Recruiting
    • Azienda Ospedaliera Fatebenefratelli
    • Contact: Gabriella Farina, MD
  • Milano, Italy
    • Recruiting
    • Ospedale S. Raffaele
    • Contact: Vanesa Gregorc
  • Monza, Italy
    • Recruiting
    • AO San Gerardo
    • Contact: Paolo Bidoli, MD
  • Padova, Italy
    • Recruiting
    • Istituto Oncologico Veneto
    • Contact: Adolfo Favaretto, MD
  • Perugia, Italy
    • Recruiting
    • Ospedale Santa Maria della Misericordia
    • Contact: Lucio Crinò, MD
  • Ravenna, Italy
    • Recruiting
    • Ospedale S MAria delle Croci
  • Reggio Emilia, Italy
    • Recruiting
    • Arcispedale Santa Maria Nuova
  • Rimini, Italy
    • Recruiting
    • AUSL Rimini-Oncologia medica
    • Contact: Maximilian Papi, MD
  • Roma, Italy
    • Recruiting
    • Istituto Nazionale Tumori Regina Elena
  • Roma, Italy
    • Recruiting
    • Ospedale S. Giovanni Addolorata
    • Contact: oLGA Martelli, MD
  • Roma, Italy
    • Recruiting
    • Policlinico Umberto I- Università la Sapienza
    • Contact: Enrico Cortesi, MD
  • Sassari, Italy
    • Recruiting
    • AOU Sassari
    • Contact: Lorenzo Cordero, MD
  • Sondalo, Italy
    • Recruiting
    • Azienda Ospedaliera Sondalo
    • Contact: Giuseppe Valmadre, MD
  • Trento, Italy
    • Recruiting
    • Ospedale Santa Chiara
    • Contact: Orazio Caffo, MD
  • Udine, Italy
    • Recruiting
    • AOU S.M. Misericordia
    • Contact: Alessandro Follador, MD
  • Verona, Italy
    • Recruiting
    • AOU Verona
    • Contact: Gianpaolo Tortora, MD
  • Forlì
    • Meldola, Forlì, Italy
      • Recruiting
      • IRCSSIstituto Scientifico Romagnolo per lo studio e la cura dei tumori IRST
      • Contact: Marco Angelo Burgio, MD
  • Pordenone
    • Aviano, Pordenone, Italy
      • Recruiting
      • Istituto Nazionale Tumori
      • Contact: Alessandra Bearz, MD
  • Ravenna
    • Faenza, Ravenna, Italy
      • Recruiting
      • Ospedale di Faenza
      • Contact: Alessandro Gamboni, MD
    • Lugo, Ravenna, Italy
      • Recruiting
      • Ospedale di Lugo
      • Contact: Gianni Michele Turolla, MD
  • Rimini
    • Cattolica, Rimini, Italy
      • Recruiting
      • AUSL Rimini-Oncologia Medica Cattolica
      • Contact: Maximilian Papi, MD
  • Turin
    • Orbassano, Turin, Italy, 10043
      • Recruiting
      • AOU San Luigi Gonzaga, Department of Oncology, University of Turin
      • Contact: Silvia Novello, MD, PhD; Phone Number: +390119026978; Email: silvia.novello@unito.it

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 70 years and older (OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Histologically or cytologically confirmed NSCLC.

• Stage IV NSCLC by the AJCC Staging Manual 7th edition (2010).
• Measurable or evaluable disease by RECIST 1.1.
• Age equal or more than 70 years.
• Performance Status 0 or 1 (by ECOG criteria).
• Adequate bone marrow function.
• Signed informed consent document (ICD).
• Men with partners in the childbearing age group must use effective contraception.
• Previous surgery for NSCLC (more than 30 days before study registration) is allowed.
• Previous radiotherapy is allowed if: the time between completion of RT and initiation of study treatment is at least 7 days,the patient has fully recovered from all toxic effects, and at least one target lesion or evaluable disease is outside the radiation field.
• Previous chemotherapy is allowed if the last dose was administered equal to or greater than 12 months ago. This chemotherapy must have been given in an adjuvant or neoadjuvant mode prior to or after a curative intent surgical resection for a NSCLC. Patient should be previously untreated for metastatic disease.
• Patients with stable brain metastases will be allowed to enroll. Stable brain metastasis is defined as no progression of brain metastases 14 days after conclusion of definitive treatment as documented by a CT scan or MRI of the brain.

Exclusion Criteria:

• Prior systemic chemotherapy or immunotherapy for advanced NSCLC.
• Prior malignancies, except: cured non-melanoma skin cancer, curatively treated in situ carcinoma of the cervix, or any other curatively treated malignancy with no evidence of disease recurrence for at least 2 years.
• Presence of uncontrolled brain or leptomeningeal metastases.
• Peripheral neuropathy or hearing loss of neural origin equal to or greater than grade 2 by CTCAE v 4.0 except if due to trauma.
• Other serious illness or medical condition, including but not limited to: congestive heart failure;myocardial infarction within 6 months;significant neurologic or psychiatric disorders that would impact study participation as judged by the treating physician; infection requiring I.V. antibiotics; tuberculosis with ongoing therapy at study entry, superior vena cava syndrome, except if controlled with radiation, active peptic ulcer disease; unstable diabetes mellitus;any contraindication to high dose corticosteroid therapy such as herpes simplex, herpes zoster, hepatitis, or other disease.
• Hypercalcemia requiring therapeutic intervention.
• Clinically significant ascites and/or pericardial effusion.
• Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80.
• Concurrent treatment with other investigational drugs.
• Patients known to harbor sensitizing EGFR mutations in exons 18, 19 and 21. Patients with resistance mutation in exon 20 will be allowed to enroll i.e. T790M and D770. The rare patient who has both a resistance mutation and a sensitizing mutation at the diagnoses will be excluded in the protocol.
• Patients whose tissue submission is not of adequate size to perform molecular testing will be excluded.
• Patients known to have translocations of ALK will also be excluded; however, testing for ALK translocation prior to study entry is not mandated.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: control arm; At discretion of the treating phisician. Common chemotherapic regimens include: Gemcitabine at 1000 or 1250 mg/m2 IV (in the vein) on day 1 and 8 of each 21 day cycle. Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 and 8 of each 21 day cycle. Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed 500mg/m2 on day 1 IV on Day 1 of each 21 day cycle. Vinorelbine 30 mg/m2 IV on day 1 and day 8 every 3 of each 21 day cycle. Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity.	Drug: Gemcitabine; Other Names: Gemzar; Drug: Docetaxel; Other Names: Taxotere; Drug: Pemetrexed; Other Names: Alimta; Drug: Carboplatin; Drug: Vinorelbine; Other Names: Navelbine
EXPERIMENTAL: experimental arm; Treatment prescriptions will be based on gene analysis: Carboplatin at an AUC of 6 IV (in the vein) on day 1 of each 21 day cycle.; Gemcitabine at 1000 mg/m2 IV on day 1 and 8 of each 21 day cycle.; Carboplatin at an AUC of 5 IV on day 1 of each 21 day cycle plus Gemcitabine at 1000 mg/m2 IV on Day 1 of each 21 day cycle.; Carboplatin at an AUC of 5 IV on Day 1 of each 21 day cycle plus Pemetrexed at 500 mg/m2 IV on Day 1 of each 21 day cycle.; Pemetrexed 500mg/m2 IV on Day 1 of each 21 day cycle.; Docetaxel 75 mg/m2 IV on Day 1 of each 21 day cycle. Or Vinorelbine 30 mg/m2 IV on day 1 and day 8 of each 21 day cycle. Number of Cycles: to a maximum of 6 cycles until progression or unacceptable toxicity.	Drug: Gemcitabine; Other Names: Gemzar; Drug: Docetaxel; Other Names: Taxotere; Drug: Pemetrexed; Other Names: Alimta; Drug: Carboplatin; Drug: Vinorelbine; Other Names: Navelbine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	primary endpoint is OS (determined from the date of randomization).Assuming an exponential survival distribution for both treatment arms and a median survival time of 8 months in the control arm we anticipate to detect an improvement of three months in OS.	from the date of randomization

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression Free survival	PFS at 6 months (determined from the date of randomization). The anticipated 6-month PFS in arm B is approximately 25% and the goal in the experimental arm is to achieve a 32% improvement to 33%.	at six months determined from the date of randomization

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
AE and SAE (according to CTCAE version 4.0)	adverse events and serious adverse events as a measure of safety and tolerability	every week from the day 1 treatment until the end of treatment (up to 18 weeks)
Rate of successfully conducted gene expression analysis in patients that have signed the informed consent document	Rate of successfully conducted gene expression analysis in patients that have signed the informed consent document	up to10 business days of submission of the tumor specimen

Collaborators and Investigators

• Sponsor: University of Turin, Italy
• Investigators: Principal Investigator: Silvia Novello, MD, PhD, University of Turin, Italy; Principal Investigator: Giorgio Vittorio Scagliotti, MD, PhD, Univerisity of Turin; Principal Investigator: Tiziana Vavalà, MD, University of Turin, Italy

Study record dates

Study Major Dates

• Study Start: July 1, 2012
• Primary Completion (ANTICIPATED): December 1, 2020
• Study Completion (ANTICIPATED): May 1, 2021

Study Registration Dates

• First Submitted: November 17, 2014
• First Submitted That Met QC Criteria: January 9, 2018
• First Posted (ACTUAL): January 17, 2018

Study Record Updates

• Last Update Posted (ACTUAL): November 4, 2020
• Last Update Submitted That Met QC Criteria: November 3, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Keywords: Elderly; Lung Cancer; NSCLC; First line; Customized chemotherapy; Pharmacogenomic-driven
• Additional Relevant MeSH Terms: Neoplasms by Site; Bronchial Diseases; Neoplasms; Lung Diseases; Lung Neoplasms; Respiratory Tract Diseases; Thoracic Neoplasms; Bronchial Neoplasms; Carcinoma, Bronchogenic; Respiratory Tract Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Phytogenic; Folic Acid Antagonists; Gemcitabine; Docetaxel; Carboplatin; Vinorelbine; Pemetrexed
• Other Study ID Numbers: 2012-001194-81